SCHEMBL970071

SCHEMBL970071

Sc1nnc(-c2ccco2)s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.62
KDM4E B2RXH2 11/20 0.59
NPC1 O15118 9/20 0.48
RAB9A P51151 9/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
POLB P06746 4/20 0.48
HSD17B10 Q99714 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
TP53 P04637 1/20 0.48
GLA P06280 1/20 0.48
APAF1 O14727 1/20 0.47
NSD2 O96028 1/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47
SAE1 Q9UBE0 1/20 0.47
UBA2 Q9UBT2 1/20 0.47
HPGD P15428 3/20 0.46
TDP1 Q9NUW8 4/20 0.45
RECQL P46063 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23212489 0.78 ALDH1A1 (0.65) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL10054150 0.77 KDM4E (0.64) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL570555 0.77 ALDH1A1 (1.00) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL10272059 0.73 KDM4E (0.58) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL10220036 0.73 KDM4E (0.58) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL8536020 0.73 KDM4E (0.58) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL6693068 0.72 SIRT1 (0.58) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL8534280 0.70 KDM4E (0.55) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL9313310 0.69 ADORA3 (0.58) ALDH1A1KDM4ENPC1RAB9APOLB
SCHEMBL10495052 0.69 ALDH1A1 (0.53) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751426-A Rosuvastatin calcium side chain containing sulfone structure, rosuvastatin calcium key intermediate and preparation method thereof 滁州市庆云医药有限公司 2025-04-04 CN claimed
CN-119751426-A Rosuvastatin calcium side chain containing sulfone structure, rosuvastatin calcium key intermediate and preparation method thereof 滁州市庆云医药有限公司 2025-04-04 CN disclosed
US-8623111-B2 Methods for creating a moist top dressing material and products related thereto BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2014-01-07 US disclosed
US-20120234219-A1 Sand Based Fungicides Board of Regents of Michigan State University 2012-09-20 US disclosed
US-8202343-B2 Sand based fungicides BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2012-06-19 US disclosed
US-8028928-B2 Spreader apparatus for sand based formulations BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2011-10-04 US disclosed
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090181849-A1 Agricultural chemical containing top dressing composition and process for use thereof MICHIGAN STATE UNIVERSITY 2009-07-16 US disclosed
US-20090151243-A1 Spreader apparatus for sand based formulations MICHIGAN STATE UNIVERSITY 2009-06-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
WO-2009064342-A1 SAND BASED FUNGICIDES AND SPREADER APPARATUS FOR TOP DRESSING COMPOSITIONS MICHIGAN STATE UNIVERSITY (US) 2009-05-22 WO disclosed
US-20090120339-A1 Spreader based fungicides MICHIGAN STATE UNIVERSITY 2009-05-14 US disclosed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 EP disclosed
US-6080772-A 2-AMINOTHIAZOLE TRIAZOLE OR TETRAZOLE COMPOUND FOR REGULATING PROTEIN TYROSINE PHOSPHATASE ACTIVITY SUGEN, INC. (US) 2000-06-27 US disclosed
US-4861787-A Nematicidal compositions CIBA-GEIGY CORPORATION (US) 1989-08-29 US disclosed
EP-0263066-A2 2-Mercapto-oxadiazole and -thiadiazole derivatives, process for their preparation and nematicides containing them CIBA-GEIGY AG (CH) 1988-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 ALDH1A1 2976/4885KDM4E 3077/4885NPC1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.